Concorde Asset Management LLC Has $493,000 Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Concorde Asset Management LLC lowered its position in Twist Bioscience Co. (NASDAQ:TWST) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,906 shares of the company’s stock after selling 495 shares during the period. Concorde Asset Management LLC’s holdings in Twist Bioscience were worth $493,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $43,992,000. Point72 Asset Management L.P. raised its holdings in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after buying an additional 300,891 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in Twist Bioscience during the second quarter worth about $9,462,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on TWST. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday. Scotiabank increased their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.78.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,057 shares of Twist Bioscience stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now directly owns 121,013 shares of the company’s stock, valued at $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 1,730 shares of Twist Bioscience stock in a transaction on Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 over the last three months. 3.92% of the stock is owned by company insiders.

Twist Bioscience Stock Up 1.9 %

Shares of NASDAQ TWST opened at $41.89 on Friday. Twist Bioscience Co. has a 52 week low of $23.07 and a 52 week high of $60.90. The firm’s fifty day moving average is $43.93 and its 200 day moving average is $46.15. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -11.57 and a beta of 1.78.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.